查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1930143

全球前列腺癌荷尔蒙疗法市场：市场规模、占有率、成长率、行业分析、依类型、应用和地区划分的考察、未来预测（2026-2034）

Prostate Cancer Hormone Therapy Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 167 Pages | 商品交期: 请询问到货日

价格

前列腺癌荷尔蒙疗法市场的成长因素

受前列腺癌发病率上升、老年男性诊断率增加以及荷尔蒙疗法策略不断进步的推动，全球前列腺癌荷尔蒙疗法市场展现出强劲的成长潜力。根据2025年的报告年份，2025年市场规模达到204.4亿美元，并在2026年成长至277.9亿美元。在长期预测期内，预计到2034年，市场规模将达到惊人的831亿美元，这反映了雄激素剥夺疗法（ADT）和新一代激素类药物的广泛应用。

荷尔蒙疗法仍然是前列腺癌治疗的基石，尤其是在晚期和转移性疾病阶段。前列腺癌的生长受到睪固酮等雄性激素的强烈影响，抑製或阻断这些荷尔蒙的治疗方法可以显着延缓疾病进展。由于其临床疗效，荷尔蒙疗法广泛用作转移性前列腺癌的第一线治疗，与其他疗法联合使用的情况也日益增多。

市场概览及关键洞察

到2025年，北美将占据前列腺癌荷尔蒙疗法市场52.30%的占有率，区域市场规模将达到106.9亿美元。这一优势得益于强有力的医疗保险政策、先进的肿瘤治疗基础设施以及创新荷尔蒙疗法的早期应用。美国凭藉高额的研发投入、强大的临床试验管道以及新药频繁获得监管部门批准，在北美市场占据领先地位。

欧洲市场占有率位居第二，这主要得益于成本效益方面的监管批准以及公众对前列腺癌的高度认知。亚太地区预计将实现最快成长，这主要得益于人口老化加剧、摄护腺癌发病率上升以及日本和中国等国家监管审批速度加快。

市场动态

市场驱动因素

荷尔蒙疗法的进步是推动市场成长的主要因素。随着时间的推移，患者往往会对传统的雄性激素剥夺疗法产生抗药性，这促使製药公司开发雄性激素受体抑制剂和联合疗法，以提高存活率。先进疗法的持续监管审批扩大治疗选择范围，无论疾病处于哪个阶段。

市场限制因子

荷尔蒙疗法抗药性的产生是主要的限制因素。在长期治疗过程中，前列腺癌细胞会透过雄性激素受体突变和替代雄性激素合成途径来适应。这些机制会降低治疗效果，需要额外的治疗干预，并影响患者的长期治疗顺从性。

市场挑战

荷尔蒙疗法会带来一些副作用，例如勃起功能障碍、性慾减退和疲劳。临床资料显示，超过 80.0%的接受雄性激素剥夺疗法（ADT）的患者会出现勃起功能障碍，约 64.0%的患者会出现性慾减退。这些副作用会显着影响患者的生活品质，并可能影响治疗顺从性。

市场机会

联合疗法的研发，特别是将雄性激素剥夺疗法（ADT）与 PARP 抑制剂或新型标靶药物联合使用的疗法，蕴藏着巨大的成长机会。临床试验结果表明，联合疗法能够提高存活率并降低死亡风险，这正推动着联合治疗策略的更广泛应用。

市场趋势

一个值得关注的市场趋势是，长效缓释製剂的核准和应用日益增多。这些长效疗法透过减少给药频率和最大限度地减少荷尔蒙波动，提高了治疗依从性，尤其是在老年患者中。多个地区的监管机构支持这些创新，以加强以患者为中心的前列腺癌治疗。

市场区隔分析

依药物类别

促性腺激素释放激素（GnRH）促效剂细分市场占据了最大的市场占有率，这得益于其在抑制睪固酮方面的显着疗效和广泛的临床应用。由于睪酮抑制速度更快以及监管审批的增加，GnRH受体拮抗剂预计将快速成长。雄性激素受体抑制剂市场也随着核准适应症的增加而显着扩张。

依疾病状态划分

转移性去势抵抗性摄护腺癌（mCRPC）市场占最大占有率，这主要得益于该疾病的高负担和频繁的监管审批。随着各公司将药物适应症扩展到更早期的疾病阶段，非转移性前列腺癌市场预计将成长更快。

依给药途径划分

口服给药因其便利性、更高的依从性以及仿製药的广泛普及而占据市场主导地位。肠外给药虽然市场占有率较小，但透过进行中的临床试验，其重要性日益凸显。

依通路划分

医院药局凭藉其专业的监管和获得先进治疗方案的管道，保持着领先的市场占有率。同时，随着数位化进程的推进，线上药局的市场占有率也在不断成长。

2025年版前列腺癌激素疗法市场报告提供了2025年、2026年和2034年的全面市场规模和价值预测，并深入分析了市场动态、趋势、细分、区域表现、竞争格局和最新发展。该分析重点关注监管环境、荷尔蒙疗法创新以及不断演变的治疗模式，这些因素共同塑造了市场的长期扩张。

北美在2025年以52.30%的市场占有率引领市场，凸显了其先进的医疗基础设施、有利的偿付政策和强大的研究生态系统的重要性。同时，欧洲和亚太地区也凭藉其经济有效的治疗方案和不断扩大的患者群体，为市场做出了显着贡献。儘管存在治疗抗药性和治疗相关副作用等挑战，但持续的研究、监管审批以及向长效製剂和联合疗法的转变缓解这些局限性。总体而言，创新、适应症的扩大以及前列腺癌在全球范围内日益严重的负担，为2034年之前的长期成长创造了有利的市场环境。

目录

第1章 引言

第2章 执行摘要

第3章 市场动态

  • 市场驱动因素
  • 市场限制因素
  • 市场机会
  • 市场趋势

第4章 主要考察

  • 主要国家和地区的摄护腺癌盛行率（2025年）
  • 主要公司的研发管线分析
  • 替代疗法概述
  • 市场上主要的新创企业
  • 主要公司的新产品发布
  • 关键产业趋势：併购、业务合作等
  • 新冠疫情对市场的影响

第5章 全球前列腺癌荷尔蒙疗法市场分析：洞察与预测（2021-2034）

  • 市场分析、洞察与预测：依药物类别划分
    • 雄性激素受体抑制剂
    • 促性腺激素释放激素（GnRH）促效剂
    • 促性腺激素释放激素（GnRH）受体拮抗剂
    • 其他
  • 市场分析、洞察与预测：依给药途径划分
    • 口服
    • 肠外给药
  • 市场分析、洞察与预测：依疾病状态划分
    • 转移性去势抵抗性摄护腺癌
    • 非转移性去势抵抗性摄护腺癌
  • 市场分析、洞察与预测：依通路划分
    • 医院药房
    • 药局和零售药房
    • 线上药房
  • 市场分析、洞察与预测：依地区划分
    • 北美
    • 欧洲
    • 亚太地区
    • 拉丁美洲
    • 中东和非洲

第6章 北美前列腺癌荷尔蒙疗法市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • 美国
    • 加拿大

第7章 欧洲前列腺癌激素疗法市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 斯堪的纳维亚
    • 欧洲其他地区

第8章 亚太地区前列腺癌激素疗法市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • 中国
    • 日本
    • 印度
    • 澳洲
    • 东南亚
    • 亚太其他地区

第9章 拉丁美洲前列腺癌激素疗法市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • 巴西
    • 墨西哥
    • 拉丁美洲其他地区

第10章 中东与非洲前列腺癌激素疗法市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • GCC国家
    • 南非
    • 中东和非洲其他地区

第11章 竞争分析

  • 全球市场占有率分析（2025）
  • 公司简介
    • Astellas Pharma Inc.
    • Pfizer Inc.
    • Johnson &Johnson Services, Inc.
    • Ferring Pharmaceuticals Inc.
    • Sumitomo Pharma Co., Ltd.（Myovant Sciences GmbH）
    • AbbVie Inc.
    • AstraZeneca
    • Accord BioPharma, Inc.
    • Bayer AG
Product Code: FBI112836

Growth Factors of prostate cancer hormone therapy Market

The global prostate cancer hormone therapy market demonstrates strong growth potential, driven by the rising prevalence of prostate cancer, increasing diagnosis rates among the aging male population, and continuous advancements in hormonal treatment strategies. As per the 2025 report year, the market was valued at USD 20.44 billion in 2025 and is projected to expand to USD 27.79 billion in 2026. Over the long-term forecast horizon, the market is expected to reach a substantial value of USD 83.1 billion by 2034, reflecting widespread adoption of androgen deprivation therapy (ADT) and next-generation hormone-based drugs.

Hormone therapy remains a cornerstone in prostate cancer treatment, particularly for advanced and metastatic disease stages. Prostate cancer growth is strongly influenced by androgens such as testosterone, and therapies that suppress or block these hormones significantly slow disease progression. Due to its clinical effectiveness, hormone therapy is commonly used as a first-line treatment in metastatic prostate cancer and increasingly in combination with other therapeutic modalities.

Market Overview and Key Insights

In 2025, North America dominated the prostate cancer hormone therapy market with a 52.30% share, accounting for a regional market value of USD 10.69 billion. This dominance is supported by strong reimbursement policies, advanced oncology infrastructure, and early adoption of innovative hormone therapies. The United States leads the region due to high research investments, robust clinical trial pipelines, and frequent regulatory approvals for novel drugs.

Europe holds the second-largest share, supported by cost-effectiveness endorsements from healthcare authorities and high disease awareness. The Asia Pacific region is projected to be the fastest-growing, driven by an expanding geriatric population, increasing prostate cancer incidence, and accelerating regulatory approvals in countries such as Japan and China.

Market Dynamics

Market Drivers

Advancements in hormonal therapies are a major driver of market growth. Traditional androgen deprivation therapy often leads to resistance over time, prompting pharmaceutical companies to develop androgen receptor inhibitors and combination therapies that improve survival outcomes. Regulatory approvals for advanced therapies continue to strengthen treatment availability across disease stages.

Market Restraints

A key restraint is the development of resistance to hormone therapy. Over prolonged treatment periods, prostate cancer cells adapt through androgen receptor mutations or alternative androgen synthesis pathways. These mechanisms reduce treatment efficacy and necessitate additional therapeutic interventions, impacting long-term treatment continuity.

Market Challenges

Hormone therapy is associated with adverse effects such as erectile dysfunction, reduced libido, and fatigue. Clinical data indicate that over 80.0% of patients undergoing ADT experience erectile dysfunction, while approximately 64.0% report loss of sexual desire. These side effects can significantly affect patient quality of life and influence therapy adherence.

Market Opportunities

Research and development of combination therapies, particularly pairing ADT with PARP inhibitors or novel targeted agents, presents strong growth opportunities. Clinical trial results demonstrating improved survival and reduced mortality risk are encouraging broader adoption of combination treatment strategies.

Market Trends

A prominent trend in the market is the increasing approval and adoption of long-acting depot formulations. These sustained-release therapies improve patient adherence by reducing dosing frequency and minimizing hormonal fluctuations, especially in elderly patients. Regulatory agencies across multiple regions are supporting such innovations to enhance patient-centric prostate cancer care.

Segmentation Analysis

By Drug Class

The Gonadotropin-Releasing Hormone (GnRH) agonists segment held the largest market share due to proven effectiveness in testosterone suppression and widespread clinical use. GnRH receptor antagonists are expected to grow rapidly owing to faster testosterone suppression and rising regulatory approvals. The androgen receptor inhibitors segment is also expanding significantly due to increasing indication approvals.

By Disease State

The metastatic castration-resistant prostate cancer (mCRPC) segment accounts for the largest share, driven by high disease burden and frequent regulatory approvals. The non-metastatic segment is anticipated to grow faster as companies expand drug indications to earlier disease stages.

By Route of Administration

The oral route dominates the market due to convenience, improved adherence, and increasing availability of generic drugs. Parenteral therapies hold a smaller share but continue to gain relevance through ongoing clinical trials.

By Distribution Channel

Hospital pharmacies maintain a leading share due to specialist oversight and access to advanced therapies, while online pharmacies are gaining traction with rising digital adoption.

Competitive Landscape

The prostate cancer hormone therapy market is moderately consolidated, with key players including Astellas Pharma Inc., Pfizer Inc., Bayer AG, and Johnson & Johnson Services, Inc.. These companies continue to strengthen their market positions through product launches, regulatory approvals, acquisitions, and strategic collaborations aimed at expanding global access to advanced hormone therapies.

Report Scope

The 2025 prostate cancer hormone therapy market report provides comprehensive coverage of market size and value for 2025, 2026, and 2034, along with detailed insights into market dynamics, trends, segmentation, regional performance, competitive landscape, and recent industry developments. The analysis emphasizes regulatory progress, innovation in hormone therapy, and the evolving treatment paradigm shaping long-term market expansion.

Conclusion

The prostate cancer hormone therapy market is set for sustained and robust expansion over the forecast period, supported by a strong clinical foundation and continuous therapeutic innovation. With a market value of USD 20.44 billion in 2025, projected to rise to USD 27.79 billion in 2026 and further escalate to USD 83.1 billion by 2034, the market outlook reflects the growing dependence on hormone-based treatments across multiple stages of prostate cancer. The central role of androgen deprivation therapy, combined with the rapid uptake of next-generation androgen receptor inhibitors and combination regimens, continues to redefine treatment standards.

North America's leadership, holding 52.30% market share in 2025, underscores the importance of advanced healthcare infrastructure, favorable reimbursement policies, and strong research ecosystems, while Europe and Asia Pacific contribute significantly through cost-effective treatment access and expanding patient populations. Despite challenges such as therapy resistance and treatment-related adverse effects, ongoing research, regulatory approvals, and the shift toward long-acting formulations and combination therapies are mitigating these limitations. Overall, the market is well-positioned for long-term growth through 2034, driven by innovation, expanding indications, and the increasing global burden of prostate cancer.

Segmentation By Drug Class

  • Androgen Receptor Inhibitors
  • Gonadotropin Releasing Hormone (GnRH) Agonist
  • Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist
  • Others

By Route of Administration

  • Oral
  • Parenteral

By Disease State

  • Metastatic Castration-Resistant Prostate Cancer
  • Non-Metastatic Castration-Resistant Prostate Cancer

By Distribution Channel

  • Hospital Pharmacies
  • Drug Stores & Retail Pharmacies
  • Online Pharmacies

By Region

  • North America (By Drug Class, Route of Administration, Disease State, Distribution Channel, and Country)
    • U.S.
    • Canada
  • Europe (By Drug Class, Route of Administration, Disease State, Distribution Channel, and Country/Sub-Region)
    • U.K.
    • Germany
    • France
    • Spain
    • Italy
    • Rest of Europe
  • Asia Pacific (By Drug Class, Route of Administration, Disease State, Distribution Channel, and Country/Sub-Region)
    • Japan
    • China
    • India
    • Australia
    • Rest of Asia Pacific
  • Latin America (By Drug Class, Route of Administration, Disease State, Distribution Channel, and Country/Sub-Region)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa (By Drug Class, Route of Administration, Disease State, Distribution Channel, and Country/Sub-Region)
    • GCC
    • South Africa
    • Rest of the Middle East & Africa

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Prevalence of Prostate Cancer - by Key Countries/Regions, 2025
  • 4.2. Pipeline Analysis, by Key Players
  • 4.3. Overview of Alternative Therapies
  • 4.4. Key Start-ups in the Market
  • 4.5. New Product Launches, by Key Players
  • 4.6. Key Industry Developments (Mergers, Acquisitions, Partnerships, etc.)
  • 4.7. Impact of COVID-19 on the Market

5. Global Prostate Cancer Hormone Therapy Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Drug Class
    • 5.1.1. Androgen Receptor Inhibitors
    • 5.1.2. Gonadotropin Releasing Hormone (GnRH) Agonist
    • 5.1.3. Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist
    • 5.1.4. Others
  • 5.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 5.2.1. Oral
    • 5.2.2. Parenteral
  • 5.3. Market Analysis, Insights and Forecast - By Disease State
    • 5.3.1. Metastatic Castration-Resistant Prostate Cancer
    • 5.3.2. Non-Metastatic Castration-Resistant Prostate Cancer
  • 5.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 5.4.1. Hospital Pharmacies
    • 5.4.2. Drug Stores & Retail Pharmacies
    • 5.4.3. Online Pharmacies
  • 5.5. Market Analysis, Insights and Forecast - Region
    • 5.5.1. North America
    • 5.5.2. Europe
    • 5.5.3. Asia Pacific
    • 5.5.4. Latin America
    • 5.5.5. Middle East & Africa

6. North America Prostate Cancer Hormone Therapy Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Drug Class
    • 6.1.1. Androgen Receptor Inhibitors
    • 6.1.2. Gonadotropin Releasing Hormone (GnRH) Agonist
    • 6.1.3. Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist
    • 6.1.4. Others
  • 6.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 6.2.1. Oral
    • 6.2.2. Parenteral
  • 6.3. Market Analysis, Insights and Forecast - By Disease State
    • 6.3.1. Metastatic Castration-Resistant Prostate Cancer
    • 6.3.2. Non-Metastatic Castration-Resistant Prostate Cancer
  • 6.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 6.4.1. Hospital Pharmacies
    • 6.4.2. Drug Stores & Retail Pharmacies
    • 6.4.3. Online Pharmacies
  • 6.5. Market Analysis, Insights and Forecast - By Country
    • 6.5.1. U.S.
    • 6.5.2. Canada

7. Europe Prostate Cancer Hormone Therapy Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Drug Class
    • 7.1.1. Androgen Receptor Inhibitors
    • 7.1.2. Gonadotropin Releasing Hormone (GnRH) Agonist
    • 7.1.3. Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist
    • 7.1.4. Others
  • 7.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 7.2.1. Oral
    • 7.2.2. Parenteral
  • 7.3. Market Analysis, Insights and Forecast - By Disease State
    • 7.3.1. Metastatic Castration-Resistant Prostate Cancer
    • 7.3.2. Non-Metastatic Castration-Resistant Prostate Cancer
  • 7.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 7.4.1. Hospital Pharmacies
    • 7.4.2. Drug Stores & Retail Pharmacies
    • 7.4.3. Online Pharmacies
  • 7.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 7.5.1. Germany
    • 7.5.2. U.K.
    • 7.5.3. France
    • 7.5.4. Italy
    • 7.5.5. Spain
    • 7.5.6. Scandinavia
    • 7.5.7. Rest of Europe

8. Asia Pacific Prostate Cancer Hormone Therapy Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Drug Class
    • 8.1.1. Androgen Receptor Inhibitors
    • 8.1.2. Gonadotropin Releasing Hormone (GnRH) Agonist
    • 8.1.3. Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist
    • 8.1.4. Others
  • 8.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 8.2.1. Oral
    • 8.2.2. Parenteral
  • 8.3. Market Analysis, Insights and Forecast - By Disease State
    • 8.3.1. Metastatic Castration-Resistant Prostate Cancer
    • 8.3.2. Non-Metastatic Castration-Resistant Prostate Cancer
  • 8.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 8.4.1. Hospital Pharmacies
    • 8.4.2. Drug Stores & Retail Pharmacies
    • 8.4.3. Online Pharmacies
  • 8.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 8.5.1. China
    • 8.5.2. Japan
    • 8.5.3. India
    • 8.5.4. Australia
    • 8.5.5. Southeast Asia
    • 8.5.6. Rest of Asia Pacific

9. Latin America Prostate Cancer Hormone Therapy Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Drug Class
    • 9.1.1. Androgen Receptor Inhibitors
    • 9.1.2. Gonadotropin Releasing Hormone (GnRH) Agonist
    • 9.1.3. Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist
    • 9.1.4. Others
  • 9.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 9.2.1. Oral
    • 9.2.2. Parenteral
  • 9.3. Market Analysis, Insights and Forecast - By Disease State
    • 9.3.1. Metastatic Castration-Resistant Prostate Cancer
    • 9.3.2. Non-Metastatic Castration-Resistant Prostate Cancer
  • 9.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 9.4.1. Hospital Pharmacies
    • 9.4.2. Drug Stores & Retail Pharmacies
    • 9.4.3. Online Pharmacies
  • 9.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 9.5.1. Brazil
    • 9.5.2. Mexico
    • 9.5.3. Rest of Latin America

10. Middle East & Africa Prostate Cancer Hormone Therapy Market Analysis, Insights and Forecast, 2021-2034

  • 10.1. Market Analysis, Insights and Forecast - By Drug Class
    • 10.1.1. Androgen Receptor Inhibitors
    • 10.1.2. Gonadotropin Releasing Hormone (GnRH) Agonist
    • 10.1.3. Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist
    • 10.1.4. Others
  • 10.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 10.2.1. Oral
    • 10.2.2. Parenteral
  • 10.3. Market Analysis, Insights and Forecast - By Disease State
    • 10.3.1. Metastatic Castration-Resistant Prostate Cancer
    • 10.3.2. Non-Metastatic Castration-Resistant Prostate Cancer
  • 10.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 10.4.1. Hospital Pharmacies
    • 10.4.2. Drug Stores & Retail Pharmacies
    • 10.4.3. Online Pharmacies
  • 10.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 10.5.1. GCC
    • 10.5.2. South Africa
    • 10.5.3. Rest of Middle East & Africa

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2025)
  • 11.2. Company Profiles
    • 11.2.1. Astellas Pharma Inc.
      • 11.2.1.1. Overview
      • 11.2.1.2. Products
      • 11.2.1.3. SWOT Analysis
      • 11.2.1.4. Recent Developments
      • 11.2.1.5. Strategies
      • 11.2.1.6. Financials (Based on Availability)
    • 11.2.2. Pfizer Inc.
      • 11.2.2.1. Overview
      • 11.2.2.2. Products
      • 11.2.2.3. SWOT Analysis
      • 11.2.2.4. Recent Developments
      • 11.2.2.5. Strategies
      • 11.2.2.6. Financials (Based on Availability)
    • 11.2.3. Johnson & Johnson Services, Inc.
      • 11.2.3.1. Overview
      • 11.2.3.2. Products
      • 11.2.3.3. SWOT Analysis
      • 11.2.3.4. Recent Developments
      • 11.2.3.5. Strategies
      • 11.2.3.6. Financials (Based on Availability)
    • 11.2.4. Ferring Pharmaceuticals Inc.
      • 11.2.4.1. Overview
      • 11.2.4.2. Products
      • 11.2.4.3. SWOT Analysis
      • 11.2.4.4. Recent Developments
      • 11.2.4.5. Strategies
      • 11.2.4.6. Financials (Based on Availability)
    • 11.2.5. Sumitomo Pharma Co., Ltd. (Myovant Sciences GmbH)
      • 11.2.5.1. Overview
      • 11.2.5.2. Products
      • 11.2.5.3. SWOT Analysis
      • 11.2.5.4. Recent Developments
      • 11.2.5.5. Strategies
      • 11.2.5.6. Financials (Based on Availability)
    • 11.2.6. AbbVie Inc.
      • 11.2.6.1. Overview
      • 11.2.6.2. Products
      • 11.2.6.3. SWOT Analysis
      • 11.2.6.4. Recent Developments
      • 11.2.6.5. Strategies
      • 11.2.6.6. Financials (Based on Availability)
    • 11.2.7. AstraZeneca
      • 11.2.7.1. Overview
      • 11.2.7.2. Products
      • 11.2.7.3. SWOT Analysis
      • 11.2.7.4. Recent Developments
      • 11.2.7.5. Strategies
      • 11.2.7.6. Financials (Based on Availability)
    • 11.2.8. Accord BioPharma, Inc.
      • 11.2.8.1. Overview
      • 11.2.8.2. Products
      • 11.2.8.3. SWOT Analysis
      • 11.2.8.4. Recent Developments
      • 11.2.8.5. Strategies
      • 11.2.8.6. Financials (Based on Availability)
    • 11.2.9. Bayer AG
      • 11.2.9.1. Overview
      • 11.2.9.2. Products
      • 11.2.9.3. SWOT Analysis
      • 11.2.9.4. Recent Developments
      • 11.2.9.5. Strategies
      • 11.2.9.6. Financials (Based on Availability)

List of Tables

  • Table 1: Global Prostate Cancer Hormone Therapy Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 2: Global Prostate Cancer Hormone Therapy Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 3: Global Prostate Cancer Hormone Therapy Market Revenue (USD billion) Forecast, by Disease State, 2021-2034
  • Table 4: Global Prostate Cancer Hormone Therapy Market Revenue (USD billion) Forecast, by Distribution Channel 2021-2034
  • Table 5: Global Prostate Cancer Hormone Therapy Market Revenue (USD billion) Forecast, by Region, 2021-2034
  • Table 6: North America Prostate Cancer Hormone Therapy Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 7: North America Prostate Cancer Hormone Therapy Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 8: North America Prostate Cancer Hormone Therapy Market Revenue (USD billion) Forecast, by Disease State, 2021-2034
  • Table 9: North America Prostate Cancer Hormone Therapy Market Revenue (USD billion) Forecast, by Distribution Channel 2021-2034
  • Table 10: North America Prostate Cancer Hormone Therapy Market Revenue (USD billion) Forecast, By Country, 2021-2034
  • Table 11: Europe Prostate Cancer Hormone Therapy Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 12: Europe Prostate Cancer Hormone Therapy Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 13: Europe Prostate Cancer Hormone Therapy Market Revenue (USD billion) Forecast, by Disease State, 2021-2034
  • Table 14: Europe Prostate Cancer Hormone Therapy Market Revenue (USD billion) Forecast, by Distribution Channel 2021-2034
  • Table 15: Europe Prostate Cancer Hormone Therapy Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 16: Asia Pacific Prostate Cancer Hormone Therapy Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 17: Asia Pacific Prostate Cancer Hormone Therapy Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 18: Asia Pacific Prostate Cancer Hormone Therapy Market Revenue (USD billion) Forecast, by Disease State, 2021-2034
  • Table 19: Asia Pacific Prostate Cancer Hormone Therapy Market Revenue (USD billion) Forecast, by Distribution Channel 2021-2034
  • Table 20: Asia Pacific Prostate Cancer Hormone Therapy Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 21: Latin America Prostate Cancer Hormone Therapy Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 22: Latin America Prostate Cancer Hormone Therapy Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 23: Latin America Prostate Cancer Hormone Therapy Market Revenue (USD billion) Forecast, by Distribution Channel 2021-2034
  • Table 24: Latin America Prostate Cancer Hormone Therapy Market Revenue (USD billion) Forecast, by Disease State, 2021-2034
  • Table 25: Latin America Prostate Cancer Hormone Therapy Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 26: Middle East & Africa Prostate Cancer Hormone Therapy Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 27: Middle East & Africa Prostate Cancer Hormone Therapy Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 28: Middle East & Africa Prostate Cancer Hormone Therapy Market Revenue (USD billion) Forecast, by Disease State, 2021-2034
  • Table 29: Middle East & Africa Prostate Cancer Hormone Therapy Market Revenue (USD billion) Forecast, by Distribution Channel 2021-2034
  • Table 30: Middle East & Africa Prostate Cancer Hormone Therapy Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034

List of Figures

  • Figure 1: Global Prostate Cancer Hormone Therapy Market Revenue Breakdown (USD billion, %) by Region, 2025 & 2034
  • Figure 2: Global Prostate Cancer Hormone Therapy Market Value Share (%), by Drug Class, 2025 & 2034
  • Figure 3: Global Prostate Cancer Hormone Therapy Market Value Share (%), by Route of Administration, 2025 & 2034
  • Figure 4: Global Prostate Cancer Hormone Therapy Market Value Share (%), by Disease State, 2025 & 2034
  • Figure 5: Global Prostate Cancer Hormone Therapy Market Value Share (%), by Distribution Channel, 2025 & 2034
  • Figure 6: Global Prostate Cancer Hormone Therapy Market Value (USD billion), by Region, 2025 & 2034
  • Figure 7: North America Prostate Cancer Hormone Therapy Market Value (USD billion), by Drug Class, 2025 & 2034
  • Figure 8: North America Prostate Cancer Hormone Therapy Market Value Share (%), by Drug Class, 2025
  • Figure 9: North America Prostate Cancer Hormone Therapy Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 10: North America Prostate Cancer Hormone Therapy Market Value Share (%), by Route of Administration, 2025
  • Figure 11: North America Prostate Cancer Hormone Therapy Market Value (USD billion), by Disease State, 2025 & 2034
  • Figure 12: North America Prostate Cancer Hormone Therapy Market Value Share (%), by Disease State, 2025
  • Figure 13: North America Prostate Cancer Hormone Therapy Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 14: North America Prostate Cancer Hormone Therapy Market Value Share (%), by Distribution Channel, 2025
  • Figure 15: North America Prostate Cancer Hormone Therapy Market Value (USD billion), By Country, 2025 & 2034
  • Figure 16: North America Prostate Cancer Hormone Therapy Market Value Share (%), By Country, 2025
  • Figure 17: Europe Prostate Cancer Hormone Therapy Market Value (USD billion), by Drug Class, 2025 & 2034
  • Figure 18: Europe Prostate Cancer Hormone Therapy Market Value Share (%), by Drug Class, 2025
  • Figure 19: Europe Prostate Cancer Hormone Therapy Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 20: Europe Prostate Cancer Hormone Therapy Market Value Share (%), by Route of Administration, 2025
  • Figure 21: Europe Prostate Cancer Hormone Therapy Market Value (USD billion), by Disease State, 2025 & 2034
  • Figure 22: Europe Prostate Cancer Hormone Therapy Market Value Share (%), by Disease State, 2025
  • Figure 23: Europe Prostate Cancer Hormone Therapy Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 24: Europe Prostate Cancer Hormone Therapy Market Value Share (%), by Distribution Channel, 2025
  • Figure 25: Europe Prostate Cancer Hormone Therapy Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 26: Europe Prostate Cancer Hormone Therapy Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 27: Asia Pacific Prostate Cancer Hormone Therapy Market Value (USD billion), by Drug Class, 2025 & 2034
  • Figure 28: Asia Pacific Prostate Cancer Hormone Therapy Market Value Share (%), by Drug Class, 2025
  • Figure 29: Asia Pacific Prostate Cancer Hormone Therapy Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 30: Asia Pacific Prostate Cancer Hormone Therapy Market Value Share (%), by Route of Administration, 2025
  • Figure 31: Asia Pacific Prostate Cancer Hormone Therapy Market Value (USD billion), by Disease State, 2025 & 2034
  • Figure 32: Asia Pacific Prostate Cancer Hormone Therapy Market Value Share (%), by Disease State, 2025
  • Figure 33: Asia Pacific Prostate Cancer Hormone Therapy Market Value (USD billion),by Distribution Channel, 2025 & 2034
  • Figure 34: Asia Pacific Prostate Cancer Hormone Therapy Market Value Share (%), by Distribution Channel, 2025
  • Figure 35: Asia Pacific Prostate Cancer Hormone Therapy Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 36: Asia Pacific Prostate Cancer Hormone Therapy Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 37: Latin America Prostate Cancer Hormone Therapy Market Value (USD billion), by Drug Class, 2025 & 2034
  • Figure 38: Latin America Prostate Cancer Hormone Therapy Market Value Share (%), by Drug Class, 2025
  • Figure 39: Latin America Prostate Cancer Hormone Therapy Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 40: Latin America Prostate Cancer Hormone Therapy Market Value Share (%), by Route of Administration, 2025
  • Figure 41: Latin America Prostate Cancer Hormone Therapy Market Value (USD billion), by Disease State, 2025 & 2034
  • Figure 42: Latin America Prostate Cancer Hormone Therapy Market Value Share (%), by Disease State, 2025
  • Figure 43: Latin America Prostate Cancer Hormone Therapy Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 44: Latin America Prostate Cancer Hormone Therapy Market Value Share (%), by Distribution Channel, 2025
  • Figure 45: Latin America Prostate Cancer Hormone Therapy Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 46: Latin America Prostate Cancer Hormone Therapy Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 47: Middle East & Africa Prostate Cancer Hormone Therapy Market Value (USD billion), by Drug Class, 2025 & 2034
  • Figure 48: Middle East & Africa Prostate Cancer Hormone Therapy Market Value Share (%), by Drug Class, 2025
  • Figure 49: Middle East & Africa Prostate Cancer Hormone Therapy Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 50: Middle East & Africa Prostate Cancer Hormone Therapy Market Value Share (%), by Route of Administration, 2025
  • Figure 51: Middle East & Africa Prostate Cancer Hormone Therapy Market Value (USD billion), by Disease State, 2025 & 2034
  • Figure 52: Middle East & Africa Prostate Cancer Hormone Therapy Market Value Share (%), by Disease State, 2025
  • Figure 53: Middle East & Africa Prostate Cancer Hormone Therapy Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 54: Middle East & Africa Prostate Cancer Hormone Therapy Market Value Share (%), by Distribution Channel, 2025
  • Figure 55: Middle East & Africa Prostate Cancer Hormone Therapy Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 56: Middle East & Africa Prostate Cancer Hormone Therapy Market Value Share (%), By Country/ Sub-region, 2025

Figure 57: Global Prostate Cancer Hormone Therapy Market Share (%), By Company, 2025